

LOOKBRITE

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for LOOKBRITE [Hydroquinone 2% + Tretinoin 0.025%
+Mometasone Furoate 0.1% Cream]

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: The combined agents in Lookbrite act by inhibiting one or more steps in the tyrosine-tyrosinase pathway of melanin synthesis. It also affects the formation of melanization and degradation of melanosomes and eventually causes necrosis of the whole melanocytes. The hyperpigmented areas fade rapidly than the surrounding normal skin.

INDICATIONS: For short term intermittent treatment of moderate to severe melasma of the face in the presence of measures for sun avoidance including use of sunscreen.

DOSAGE AND ADMINISTRATION: LOOKBRITE cream should be applied preferably once daily, in the evening. Duration of application would be determined by the physician, depending on the response.

CONTRAINDICATION: LOOKBRITE cream is contra-indicated in those patients with prior history of allergic reaction to hydroquinone, tretinoin and mometasone furoate.

WARNINGS & PRECAUTIONS: The safety of LOOKBRITE cream during pregnancy and children (below 12 years) has not been established. Caution should be exercised when LOOKBRITE cream is administered to nursing mothers. LOOKBRITE cream is strictly for external use only. Avoid contact with eyes, mouth and mucous membranes. Exposure to sunlight or ultra-violet light will cause repigmentation of bleached areas.

DRUG INTERACTIONS: None

ADVERSE REACTIONS: The adverse reactions reported are dryness, fissuring of paranasal and infraorbital areas, erythema and stinging. Occasional hyper-sensitivity may develop.

MARKETED BY:

TORRENT[™]
PHARMA

TORRENT PHARMACEUTICALS LTD.

IN/LOOKBRITE/MAR 2026/01/ABPI

(Additional information is available on request)